We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $214M
1-Year Est. Return 185.33%
This Fund
S&P 500
This Quarter Est. Return
+47.89%
1 Year Est. Return
+185.33%
3 Year Est. Return
+327.48%
5 Year Est. Return
+458.62%
10 Year Est. Return
+1,549.55%
AUM
$214M
AUM Growth
+$38.2M
Cap. Flow
-$12.5M
Cap. Flow %
-5.84%
Top 10 Hldgs %
59.94%
Holding
87
New
14
Increased
17
Reduced
22
Closed
15

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$3.66M
2
VIR icon
Vir Biotechnology
VIR
+$2.09M
3
ABVX
Abivax
ABVX
+$1.92M
4
HALO icon
Halozyme
HALO
+$1.58M
5
BIOA
BioAge Labs
BIOA
+$1.25M

Top Sells

Rank Stock Value
1
KLAC icon
KLA
KLAC
+$4.04M
2
CMPS
Compass Pathways
CMPS
+$3.5M
3
GPCR icon
Structure Therapeutics
GPCR
+$3.36M
4
OCUL icon
Ocular Therapeutix
OCUL
+$2.71M
5
NVCR icon
NovoCure
NVCR
+$2.21M

Sector Composition

Rank Sector Weight
1 Healthcare 63.39%
2 Technology 32.27%
3 Energy 3.51%
4 Materials 0.53%
5 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
76
IDEAYA Biosciences
IDYA
$3.85B
– –
-16,860
Closed -$562K
KALV
77
DELISTED
KalVista Pharmaceuticals
KALV
– –
-57,000
Closed -$1.15M
NVCR icon
78
NovoCure
NVCR
$2.09B
– –
-202,330
Closed -$2.21M
OM icon
79
Outset Medical
OM
$67.7M
– –
-98,882
Closed -$380K
PHR icon
80
Phreesia
PHR
$682M
– –
-14,300
Closed -$120K
RARE icon
81
Ultragenyx Pharmaceutical
RARE
$1.51B
– –
-62,000
Closed -$1.3M
RCKT icon
82
Rocket Pharmaceuticals
RCKT
$425M
– –
-127,025
Closed -$455K
RCUS icon
83
Arcus Biosciences
RCUS
$3.77B
– –
-25,889
Closed -$559K
RGNX icon
84
Regenxbio
RGNX
$590M
– –
-66,270
Closed -$555K
VRDN icon
85
Viridian Therapeutics
VRDN
$2.6B
– –
-20,100
Closed -$393K
VSTM icon
86
Verastem
VSTM
$736M
– –
-150,000
Closed -$795K
ZNTL icon
87
Zentalis Pharmaceuticals
ZNTL
$375M
– –
-17,503
Closed -$41K
1 2 3
4

Similar funds

EFIC
Eliot Finkel Investment Counsel Beverly Hills, California $214M AUM 62.72% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
TCM
Tassel Capital Management Matthews, North Carolina $214M AUM 16.99% 1-Year Est. Return
EFS
Econ Financial Services Harrisburg, Pennsylvania $214M AUM 10.53% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return
KWM
Kingsman Wealth Management Pensacola, Florida $214M AUM 46.9% 1-Year Est. Return
FA
Fortis Advisors Wayne, Pennsylvania $214M AUM 41.3% 1-Year Est. Return
MSWM
Mader & Shannon Wealth Management Kansas City, Missouri $214M AUM 23.75% 1-Year Est. Return

Birchview Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Birchview Capital held 87 positions worth $214M, up 22% from $176M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Birchview Capital withdrew a net $12.5M in Q2 2026, closing 15 positions and reducing 22 holdings. Its most notable exit was NovoCure, an estimated $2.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 73% a quarter earlier, followed by Technology and Energy.

Against the trend, Birchview Capital opened a new position in Vir Biotechnology worth $2.24M.

  • Birchview Capital's largest Q2 2026 buy was Vir Biotechnology: 220,000 shares worth $2.24M.
  • Birchview Capital added most to Nektar Therapeutics in Q2 2026, an estimated $3.66M increase.
  • Birchview Capital's biggest Q2 2026 reduction was KLA, cutting an estimated $4.04M.
  • Birchview Capital fully exited NovoCure in Q2 2026, selling an estimated $2.21M.
  • Birchview Capital's ten largest holdings make up 60% of its $214M portfolio in Q2 2026.
  • Birchview Capital opened 14 new positions and closed 15 in Q2 2026.
  • Birchview Capital's portfolio value rose 22% quarter-over-quarter to $214M.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.